By Jerad Winslet From Winston View

WuXi PharmaTech (Cayman) Inc. (ADR) (NYSE:WX) traded negative at $39.81. On an intraday basis, the price dropped -0.23 points or -0.58%. The composite uptick value was $2.89 million while the combined downtick value was $1. The net money flow was $1.89 million while the up/down ratio was not very comforting at 2.88. However, a positive money flow is a sign that the market is still confident about the stock. The counter on a weekly note has seen a change in share price of 2.78%.According to the trading data, the counter saw a block trade with $1.71 million in upticks and $0 million in downticks. The up/down ratio for the block was calculated to be 0. The net money flow for the block trade was 1.71.

WuXi PharmaTech (Cayman) Inc. (ADR) (NYSE:WX) ended the most recent trading session with positive gains. The shares of the WuXi PharmaTech (Cayman) Inc. (ADR) (NYSE:WX), which opened the session at $40.32, peaked out after touching $40.79 and closed the day with a gain of 0.1% or 0.04 points at $40.08. The bulls had to fight hard to eke out gains as some serious selling pressure caused a price nosedive pushing the price towards $39.63, which was the days low. At close, the volume was recorded at 608,264 shares. The market cap of the company stands at $2,806 million and the number of shares outstanding is 70,019,000.

WuXi PharmaTech (Cayman) Inc. (WuXi) is a pharmaceutical, biotechnology and medical device research and development (R&D) outsourcing company, with operations in Peoples Republic of China and the United States. The Company provides a portfolio of laboratory and manufacturing services throughout the R&D process to its customers, which include the worlds pharmaceutical, biotechnology and medical device companies. Its services are designed to assist its global customers in shortening the time and lowering the cost of pharmaceutical and medical device R&D by providing outsourcing solutions. The Company has two segments: Laboratory services and Manufacturing services segment. In March 2014, WuXi Genome Center purchased Illumina HiSeq X Ten sequencing system.

For more on this story go to: http://www.winstonview.com/large-inflow-of-money-witnessed-in-wuxi-pharmatech-cayman-inc-adr-shares/338641/
IMAGE: www.fastcompany.com